In one paragraphArticle in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
York PosorDepartment of Oncology, University College London (UCL) Cancer Institute, University College London, London WC1E 6DD, United Kingdom.ORCID 0000-0002-4699-5715 Sarah E ConduitDepartment of Oncology, University College London (UCL) Cancer Institute, University College London, London WC1E 6DD, United Kingdom.ORCID 0000-0002-5075-8851 Wayne PearceDepartment of Oncology, University College London (UCL) Cancer Institute, University College London, London WC1E 6DD, United Kingdom.ORCID 0000-0001-5407-4767 Daniele MorelliDepartment of Oncology, University College London (UCL) Cancer Institute, University College London, London WC1E 6DD, United Kingdom.ORCID 0000-0002-3714-6658 Georgia ConstantinouDepartment of Oncology, University College London (UCL) Cancer Institute, University College London, London WC1E 6DD, United Kingdom.
Maria WhiteheadDepartment of Oncology, University College London (UCL) Cancer Institute, University College London, London WC1E 6DD, United Kingdom.
Neil J SebireNational Institute for Health and Care Research Great Ormond Street Hospital (NIHR GOSH) Biomedical Research Centre at University College London, London WC1N 1EH, United Kingdom.
Cheryl L ScudamoreExepathology, Devon EX5 2FN, United Kingdom.
Henning WalczakDepartment of Oncology, University College London (UCL) Cancer Institute, University College London, London WC1E 6DD, United Kingdom.ORCID 0000-0002-6312-4591 Bart VanhaesebroeckDepartment of Oncology, University College London (UCL) Cancer Institute, University College London, London WC1E 6DD, United Kingdom.ORCID 0000-0002-7074-3673 Funding
Cancer Research UK (CRUK) A27323Cancer Research UK (CRUK) C23338/A15965Cancer Research UK (CRUK) C23338/A25722Cancer Research UK (CRUK) C416/A29287Deutsche Forschungsgemeinschaft (DFG) SFB1399 [413326622] project A09Deutsche Forschungsgemeinschaft (DFG) SFB1399 [413326622] project C06Deutsche Forschungsgemeinschaft (DFG) SFB1403 [414786233] project A10Deutsche Forschungsgemeinschaft (DFG) SFB1403 [414786233] project A12Deutsche Forschungsgemeinschaft (DFG) SFB1530 [455784452] project A03Deutsche Forschungsgemeinschaft (DFG) SFB1530 [455784452] project B02EC | European Research Council (ERC) 294880EC | Horizon Europe | Excellent Science | HORIZON EUROPE Marie Sklodowska-Curie Actions (MSCA) 656778EC | Horizon Europe | Excellent Science | HORIZON EUROPE Marie Sklodowska-Curie Actions (MSCA) GA:838559European Molecular Biology Organization (EMBO) ALTF 1227-2014UKRI | Biotechnology and Biological Sciences Research Council (BBSRC) BB/I007806/1UKRI | Biotechnology and Biological Sciences Research Council (BBSRC) BB/R017972/1UKRI | Biotechnology and Biological Sciences Research Council (BBSRC) BB/W007460/1UKRI | Medical Research Council (MRC) MR/ S00811X/1Wellcome Trust 214342Wellcome Trust (WT) 214342/Z/18/Z
6 · The paper itselfAbstract
The organismal roles of the class II PI3K isoform PI3K-C2α remain poorly understood. Recent studies have found PI3K-C2α to promote arterial thrombosis and breast cancer metastasis, generating interest in this kinase as a drug target, with small molecule PI3K-C2α inhibitors now available. However, the consequences of systemic PI3K-C2α inactivation in the nondiseased, postnatal state are largely unknown. Here, we show that induction of genetic PI3K-C2α inactivation in adult mice is well tolerated, without adverse effects on normal physiology. Surprisingly, however, mice with inactive PI3K-C2α display strong sensitization to challenge with bacterial lipopolysaccharide (LPS), a model of endotoxic shock. This sensitization is recapitulated by vascular endothelial-specific deletion of PI3K-C2α. Furthermore, sensitization to LPS can be fully rescued by disabling extrinsic induction of cell death by combined caspase-8- and RIPK3 deficiency. These observations validate the tolerability of systemic PI3K-C2α inhibition in principle but reveal an unexpected role for PI3K-C2α in the regulation of extrinsic cell death pathways.
Indexed as
Phosphatidylinositol 3-KinasesShock, SepticAnimalsCaspase 8Cell DeathLipopolysaccharidesMiceMice, Inbred C57BLMice, KnockoutReceptor-Interacting Protein Serine-Threonine KinasesSignal TransductionCaspase 8LipopolysaccharidesPhosphatidylinositol 3-KinasesReceptor-Interacting Protein Serine-Threonine Kinasesendotoxic shockphosphoinositidePI3Kregulated cell deathvascular endothelia
Identifiers
PMID40674428
PMCPMC12304892
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390